Italia markets open in 2 hours 55 minutes

180 Life Sciences Corp. (ATNF)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,4600-0,1900 (-11,52%)
Alla chiusura: 04:00PM EDT
1,4700 +0,01 (+0,68%)
Dopo ore: 07:59PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,6500
Aperto1,6001
Denaro0,0000 x 0
Domanda0,0000 x 0
Min-Max giorno1,4600 - 1,6300
Intervallo di 52 settimane1,3100 - 22,6100
Volume54.229
Media Volume144.967
Capitalizzazione1,375M
Beta (mensile su 5 anni)0,45
Rapporto PE (ttm)N/D
EPS (ttm)-30,1200
Prossima data utili13 ago 2024 - 19 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

    PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately e

  • GlobeNewswire

    180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

    PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing of a public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants will be immediately exercisable at an ex

  • GlobeNewswire

    180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

    PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“Pharmacokinetic” or “PK”) study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally. The PK study will seek to determine